WO2000073415A3 - A method for the transfer of antigens to dendritic cells - Google Patents

A method for the transfer of antigens to dendritic cells Download PDF

Info

Publication number
WO2000073415A3
WO2000073415A3 PCT/EP2000/004712 EP0004712W WO0073415A3 WO 2000073415 A3 WO2000073415 A3 WO 2000073415A3 EP 0004712 W EP0004712 W EP 0004712W WO 0073415 A3 WO0073415 A3 WO 0073415A3
Authority
WO
WIPO (PCT)
Prior art keywords
transfer
dendritic cells
antigens
cells
cocultivation
Prior art date
Application number
PCT/EP2000/004712
Other languages
French (fr)
Other versions
WO2000073415A2 (en
Inventor
Catia Traversari
Vincenzo Russo
Claudio Bordignon
Original Assignee
Genera Spa
Catia Traversari
Vincenzo Russo
Claudio Bordignon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Spa, Catia Traversari, Vincenzo Russo, Claudio Bordignon filed Critical Genera Spa
Priority to JP2001500731A priority Critical patent/JP2003501019A/en
Priority to CA002375349A priority patent/CA2375349A1/en
Priority to KR1020017015173A priority patent/KR20020013563A/en
Priority to EP00936788A priority patent/EP1185626A2/en
Priority to AU52159/00A priority patent/AU772703B2/en
Priority to IL14677700A priority patent/IL146777A0/en
Publication of WO2000073415A2 publication Critical patent/WO2000073415A2/en
Publication of WO2000073415A3 publication Critical patent/WO2000073415A3/en
Priority to HK02108610.1A priority patent/HK1047131A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464496—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Abstract

A method for antigen transfer to dendritic cells, comprising cocultivation of DCs with cells transfected with, or expressing the, desired antigens.
PCT/EP2000/004712 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells WO2000073415A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001500731A JP2003501019A (en) 1999-05-28 2000-05-24 Transferring antigens to dendritic cells
CA002375349A CA2375349A1 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
KR1020017015173A KR20020013563A (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
EP00936788A EP1185626A2 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
AU52159/00A AU772703B2 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
IL14677700A IL146777A0 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
HK02108610.1A HK1047131A1 (en) 1999-05-28 2002-11-29 A method for the transfer of antigens to dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI99A001180 1999-05-28
IT1999MI001180A IT1312570B1 (en) 1999-05-28 1999-05-28 METHOD FOR TRANSFER OF DENDRITIC CELL ANTIGENS.

Publications (2)

Publication Number Publication Date
WO2000073415A2 WO2000073415A2 (en) 2000-12-07
WO2000073415A3 true WO2000073415A3 (en) 2001-03-01

Family

ID=11383060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004712 WO2000073415A2 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells

Country Status (10)

Country Link
EP (1) EP1185626A2 (en)
JP (1) JP2003501019A (en)
KR (1) KR20020013563A (en)
CN (1) CN1187442C (en)
AU (1) AU772703B2 (en)
CA (1) CA2375349A1 (en)
HK (1) HK1047131A1 (en)
IL (1) IL146777A0 (en)
IT (1) IT1312570B1 (en)
WO (1) WO2000073415A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506596B2 (en) 2000-06-01 2003-01-14 Anna-Lena Spetz-Holmgren Method of DNA transfer
CN100392074C (en) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 Dendritic cell tumor vaccine and its preparation and use
KR20130061753A (en) * 2005-04-08 2013-06-11 아르고스 쎄라퓨틱스 인코포레이티드 Dendritic cell compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006723A1 (en) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Method of marking eukaryotic cells by the use of a cell surface receptor as a marker
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
EP0904786A1 (en) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Tumor vaccination by the use of antigen transduced autologous cells
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006723A1 (en) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Method of marking eukaryotic cells by the use of a cell surface receptor as a marker
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
EP0904786A1 (en) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Tumor vaccination by the use of antigen transduced autologous cells
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBERT ET AL: "Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I", IMMUNOLOGIST,CA,HOGREFE AND HUBER PUBLISHERS, TORONTO, vol. 6, no. 5, September 1998 (1998-09-01), pages 194 - 198, XP002119454, ISSN: 1192-5612 *
ALBERT MATTHEW L ET AL: "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.", NATURE (LONDON), vol. 392, no. 6671, 5 March 1998 (1998-03-05), pages 86 - 89, XP002154749, ISSN: 0028-0836 *
RUSSO V ET AL: "Acquisition of intact allogeneic HLA molecules by human dendritic cells.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 678a, XP002154751, ISSN: 0006-4971 *
RUSSO V ET AL: "Cocultivation of non-diving dendritic cells with a retroviral vector-producing cell line allows transfer of the relevant antigens by a vector-independent mechanism.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 667A, XP000971149, ISSN: 0006-4971 *
RUSSO VINCENZO ET AL: "Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 5, 29 February 2000 (2000-02-29), Feb. 29, 2000, pages 2185 - 2190, XP002154750, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU772703B2 (en) 2004-05-06
ITMI991180A1 (en) 2000-11-28
WO2000073415A2 (en) 2000-12-07
HK1047131A1 (en) 2003-02-07
JP2003501019A (en) 2003-01-14
IL146777A0 (en) 2002-07-25
CN1187442C (en) 2005-02-02
IT1312570B1 (en) 2002-04-22
KR20020013563A (en) 2002-02-20
CA2375349A1 (en) 2000-12-07
CN1360628A (en) 2002-07-24
EP1185626A2 (en) 2002-03-13
AU5215900A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
AU2001282123A1 (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells
AU2001238677A1 (en) Method for preparing anti-mif antibodies
AU1292700A (en) Immune cells having predefined biological specificity, comprising chimeric t cell receptor
ZA200108855B (en) Method for the preparation of citalopram.
WO1999036511A3 (en) Feline immunodeficiency virus gene therapy vectors
HK1049002A1 (en) Method for the preparation of citalopram.
HK1044342A1 (en) Method for the preparation of 5-cyanophthalide.
AU2002230470A1 (en) Process for preparing pouches
HK1047086A1 (en) Method for the preparation of citalopram.
HK1054378A1 (en) Method for the preparation of citalopram.
EP1156042A4 (en) Process for the preparation of glycerol carbonate
AUPQ485999A0 (en) P. gingivalis antigenic composition
HK1052702A1 (en) Method for the preparation of 5-carboxyphthalide.
WO2001040242A3 (en) 6-o-methylerythromycin a crystal form iii
AU2001294577A1 (en) Methods for preparing interferon producing dentitric cells
ZA200007458B (en) Method of preparing a fuel cell.
MXPA03000585A (en) Fermentation process for the preparation of l-threonine.
HK1046443A1 (en) Rate adjusting method for mechanical timepieces.
AU1962600A (en) Antibodies binding to the aav capsid, antibodies modifying cytotropism, method for targeted gene transfer
AU1097301A (en) Humanization of non-human, mammalian antibodies
WO2000073415A3 (en) A method for the transfer of antigens to dendritic cells
IL148266A0 (en) Apo-2 receptor antibodies
AU6726598A (en) Method for generating embryogenic cell cultures for the production of transgenicbananas (musa spp.)
AU2002223541A1 (en) Deltamethrin-containing, water-dispersible granular material
AU5585700A (en) Process for making 2,4,6, 8,10,12- hexanitro- 2,4,6,8,10, 12- hexa azatetracyclo(5.5.0. 05,9.03,11} -dodecane

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808155.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000936788

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 500731

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2375349

Country of ref document: CA

Ref document number: 2375349

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017015173

Country of ref document: KR

Ref document number: 52159/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09979308

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017015173

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000936788

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 52159/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000936788

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015173

Country of ref document: KR